seretide diskus 50 mikrog / 100 mikrog
glaxosmithkline as - salmeterolxinafoat / flutikasonpropionat - inhalasjonspulver, dosedispensert - 50 mikrog / 100 mikrog
seretide diskus 50 mikrog / 250 mikrog
glaxosmithkline as - salmeterolxinafoat / flutikasonpropionat - inhalasjonspulver, dosedispensert - 50 mikrog / 250 mikrog
horstem
equicord s.l. - equine navlestreng mesenchymal stem cells - andre legemidler for forstyrrelser i muskel-skjelettsystemet - hester - reduksjon av halthet forbundet med mild til moderat degenerative joint sykdom (artrose) i hester.
bondenza (previously ibandronic acid roche)
roche registration ltd. - ibandronsyre - osteoporose, postmenopausale - legemidler til behandling av bein sykdommer - behandling av osteoporose hos postmenopausale kvinner med økt risiko for brudd. en reduksjon i risiko for vertebrale frakturer har blitt vist. effekten på femoral-hals brudd har ikke blitt etablert.
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. effekten av imatinib på utfallet av bein marg transplantasjon har ikke fastsatt. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. erfaring med imatinib hos pasienter med mds/mpd forbundet med pdgfr gene re-ordninger er svært begrenset. det er ingen kontrollerte studier som viser en klinisk nytte eller økt overlevelse for disse sykdommer.
ebetrex 20 mg/ ml
ebewe pharma ges.m.b.h nfg. kg - metotreksatdinatrium - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 20 mg/ ml
orfiril retard 300 mg
desitin arzneimittel gmbh - natriumvalproat - depottablett - 300 mg
xeomin 100 e
merz pharmaceuticals gmbh, frankfurt, tyskland - botulinumtoksin type a - pulver til injeksjonsvæske, oppløsning - 100 e
xeomin 50 e
merz pharmaceuticals gmbh, frankfurt, tyskland - botulinumtoksin type a - pulver til injeksjonsvæske, oppløsning - 50 e